Intervju i Dagens Industri om AlzeCures mÄngmiljardsaffÀren med Eli Lilly
Se intervjun hÀr: Alzecure i möjligt miljardavtal med Eli Lilly
AlzeCure Pharma som utvecklar smĂ„molekylĂ€ra lĂ€kemedelskandidater för CNS-sjukdomar med fokus pĂ„ Alzheimers sjukdom och smĂ€rta, har meddeladat att bolaget har ingĂ„tt ett samarbets- och utlicensieringsavtal med lĂ€kemedelsbolaget Eli Lilly and Company (âLillyâ) avseende de globala rĂ€ttigheterna till Alzheimerprojektet Alzstatin ACD680. AlzeCure kommer att erhĂ„lla 10 miljoner USD i upfrontbetalning, utvecklings- och kommersiella milstolpsbetalningar samt royalties i det medelhöga ensiffriga procentintervallet pĂ„ produktförsĂ€ljningen. Det totala avtalsvĂ€rdet, exklusive royaltybetalningar, kan överstiga 1 miljard USD.
Till press releasen: AlzeCure Pharma ingĂ„r samarbets- och utlicensieringsavtal med Lilly för Alzheimerprojekt â AlzeCure Pharma
#alzecure #Alzstatin #gammasecretasmodulator #alzheimer #dementia #neuroscience #alzheimerfonden #nordnet #avanza #redeye #aktiespararna #swedbank #analysguiden #finwire #placera #abgsundalcollier
AlzeCure Pharma ingÄr samarbets- och utlicensieringsavtal med Lilly för Alzheimerprojekt
AlzeCure Pharma AB (publ) (âAlzeCureâ) (FN STO: ALZCUR), som utvecklar smĂ„molekylĂ€ra lĂ€kemedelskandidater för CNS-sjukdomar med fokus pĂ„ Alzheimers sjukdom och smĂ€rta, har meddelat att bolaget har ingĂ„tt ett samarbets- och utlicensieringsavtal med lĂ€kemedelsbolaget Eli Lilly and Company (âLillyâ) avseende de globala rĂ€ttigheterna till Alzheimerprojektet Alzstatin ACD680. AlzeCure kommer att erhĂ„lla 10 miljoner USD i upfrontbetalning, utvecklings- och kommersiella milstolpsbetalningar samt royalties i det medelhöga ensiffriga procentintervallet pĂ„ produktförsĂ€ljningen. Det totala avtalsvĂ€rdet, exklusive royaltybetalningar, kan överstiga 1 miljard USD.
Alzstatin ACD680 Ă€r en gamma-sekretasmodulator som minskar produktionen av det skadliga amyloid-beta-proteinet AÎČ42, vilket utgör byggstenen i de amyloida plack som man finner i hjĂ€rnan hos patienter med Alzheimers sjukdom. Dessutom ökar ACD680 produktionen av kortare, ofarliga AÎČ-proteiner, AÎČ37 och AÎČ38, vilka kan minska ihopklumpningen av AÎČ42 och dĂ€rmed Ă€ven reducera uppbyggnaden av skadliga plack i hjĂ€rnan.
âGamma-sekretas modulatorer, som vi har utvecklat inom Alzstatin-plattformen, Ă€r smĂ„molekylĂ€ra lĂ€kemedel dĂ€r verkningsmekanismen har en stark genetisk koppling till sjukdomenâ, sĂ€ger Johan Sandin, Chief Scientific Officer pĂ„ AlzeCure Pharma.
âFörhoppningen Ă€r att Alzstatin-substanserna ska kunna anvĂ€ndas för att motverka Ă„teruppbyggnaden av skadligt amyloid i hjĂ€rnan. PĂ„ lĂ€ngre sikt kan dessa substanser ocksĂ„ fungera som en förebyggande behandling för att förhindra utvecklingen av Alzheimers sjukdomâ, sĂ€ger AlzeCures vd Martin Jönsson.
âAvtalet med Lilly Ă€r en viktig milstolpe för AlzeCure och Alzstatinâ, fortsĂ€tter AlzeCures vd Martin Jönsson
LĂ€s pressreleasen hĂ€r: AlzeCure Pharma ingĂ„r samarbets- och utlicensieringsavtal med Lilly för Alzheimerprojekt â AlzeCure Pharma
#alzecure #Alzstatin #gammasecretasmodulator #alzheimer #dementia #neuroscience #alzheimerfonden #nordnet #avanza #redeye #aktiespararna #swedbank #analysguiden #finwire #placera #abgsundalcollier
AlzeCure Pharma enters Collaboration & Out-licensing Agreement with Lilly for Alzheimerâs project
AlzeCure Pharma AB (publ) (âAlzeCureâ) (FN STO: ALZCUR), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimerâs disease and pain, announced today that the company has entered into a collaboration and out-licensing agreement with the pharmaceutical company Eli Lilly and Company (âLillyâ) regarding the global rights to the Alzheimerâs project Alzstatin ACD680.
AlzeCure will receive an upfront payment of $10 million USD, development and commercial milestones, and tiered mid-single digit royalties on sales. The total deal value, excluding royalty payments, may exceed $1 billion USD.
Alzstatin ACD680 is a gamma-secretase modulator that aims to reduce the production of the harmful amyloid-beta protein, AÎČ42, which forms the building blocks of the amyloid plaques found in the brains of Alzheimerâs patients. In addition, ACD680 is designed to increase the production of shorter, benign AÎČ proteins, AÎČ37 and AÎČ38, which may reduce the aggregation of AÎČ42, thereby also reducing the build-up of harmful plaques in the brain.
âGamma-secretase modulators, which we have developed within the Alzstatin platform, are small-molecule drugs where the mechanism has a strong genetic link to the disease,â says Johan Sandin, Chief Scientific Officer at AlzeCure Pharma.
âThe Alzstatin compounds are hoped to be used to counteract re-accumulation of harmful amyloid in the brain. In the long term, these compounds may also serve as a preventive treatment to prevent the development of Alzheimerâs disease,â says AlzeCureâs CEO Martin Jönsson.
âThe agreement with Lilly is an important milestone for AlzeCure and Alzstatin,â continues AlzeCureâs CEO Martin Jönsson.
Read the press release here: AlzeCure Pharma enters into a collaboration and out-licensing agreement with Lilly for Alzheimerâs project â AlzeCure Pharma
#alzecure #Alzstatin #gammasecretasmodulator #alzheimer #dementia #neuroscience #alzheimerfonden #nordnet #avanza #redeye #aktiespararna #swedbank #analysguiden #finwire #placera #abgsundalcollier
BioStock Panel on the Development in the Alzheimerâs Field
- AlzeCure, Alzinova & BioArctic
I was pleased to be invited to Market Signal, BioStockâs studio program about Nordic life science, to discuss the current development in the Alzheimer's field, together with Alzinovaâs CEO Tord Labuda and BioArcticâs CFO, Anders Martin-Löf.
The episode airs on Wednesday morning on BioStock, tune in!
See the panel discussion at BioStock: https/biostock.se
#alzinova #alzecure #bioarctic #biostock #alzheimers #dementia Martin JönssonStiftelsen Flemingsberg Science BioArctic Alzinova AB Tord Labuda
Anders Martin-Löf Cecilia Hallström, PhD Jonas Söderström
AlzeCure Pain Seminar on TrkA-NAM for Osteoarthritis
- Tuesday May 26, 14:00 CEST
AlzeCure Pharma will host a live online seminar on 26 May from 14:00 to 15:00 CEST focusing on ACD137, the leading drug candidate in the TrkA-NAM pain project.
The company recently published new results* for the TrkA-NAM pain project ACD137, and the purpose of the presentations is to explain the background and opportunities for ACD137. This includes pain indications such as osteoarthritis and chemotherapy-induced neuropathic pain, areas with significant unmet medical needs.
- The presentations will be followed by a Q&A session where participants can submit questions.
The presenters from AlzeCure are Martin Jönsson (CEO), Dr. MÀrta Segerdahl (Chief Medical Officer), and Dr. Pontus Forsell (Head of Discovery & Research).
Hosted in collaboration with Finwire, the event requires no prior registration and can be followed via:
https://t.co/o5prQ0MbIS
The presentations will be conducted in English and will also be available for later viewing on AlzeCureâs website: https://t.co/WLSBtk8DHn
AGENDA:
14:00 Introduction to AlzeCure Pharma and project status â Martin Jönsson, CEO
14:05 TrkA-NAM in pain â Major unmet medical needs & indication areas â Dr. MĂ€rta Segerdahl, CMO
14:20 TrkA-NAM â Next-generation non-opioid analgesics â Dr. Pontus Forsell, Head of Discovery & Research
14:40 Q&A â Martin Westerlund, moderator FinWire
14:55 Concluding Remarks â Martin Jönsson
New publication on TrkA-NAM - Forsell P, et al. Scand J Pain. 2026 Apr 27;26(1). https://t.co/rBiOvjmmQn
#trkanam #ACD123 #alzecure #painmanagement #osteoarthritis #neuropathicpain #chemotherapyinducedneuropathicpain #cna #neuroscience AlzeCure Pharma Pontus Forsell Martin Jönsson MÀrta Segerdahl Finwire Media
AlzeCure Presents at ABG Investor Day
- May 21 - Come & Join - Welcome đ«” đ«”
AlzeCure Pharma has been invited to present live at ABG Investor Day May 21, at 13:45 CET.
Our CEO Martin Jönsson will share insights into the company's innovative Alzheimer's and pain pipeline and ongoing development in pain projects and in the Q&A he will be joined by AlzeCureâs Chief Scientific Officer Johan Sandin.
đ See us live: https://t.co/PlrcPDfJ7z
You also have the opportunity to apply to participate in person at the event in Stockholm City, at Hotel At Six Brunkebergstorg 6: https://t.co/7amIoMqDdn
Afterwards the presentation will be published at our website under interviews and presentations: https://t.co/WLSBtk8DHn
To the press release: https://t.co/btsGQ7aWMs
#AlzeCure #HealthcareInnovation #Biotech #InvestorRelations Avanza Bank Nordnet Bank AB #alzheimers #alzstatin #neurorestore #CNS #DrugDevelopment AlzeCure Pharma Martin Jönsson ABG Sundal Collier Life Science Cluster Flemingsberg Stiftelsen Flemingsberg Science
AlzeCure Presents at Redeye Investor Forum
- May 21 - Welcome đ«” đ«”
AlzeCure Pharma has been invited to present live at Redeye Investor Forum event on May 21 at 15:20 CET.
Our CEO Martin Jönsson will share insights into the company's innovative Alzheimer's and pain pipeline and ongoing development in pain projects and in the Q&A he will be joined by AlzeCureâs Chief Scientific Officer Johan Sandin.
đ See us live: https://t.co/bl66iIXMCa
Afterwards the presentation will be published at our website inter interviews and presentations: https://t.co/WLSBtk8DHn
To the press release: https://t.co/MxKv1PU9ss
#AlzeCure #HealthcareInnovation #Biotech #InvestorRelations
#Redeye #CNS #DrugDevelopment Johan Sandin Martin Jönsson AlzeCure Pharma Redeye Group Life Science Cluster Flemingsberg Stiftelsen Flemingsberg Science
Intervju med AlzeCures vd Martin Jönsson om bolagets senaste kvartalsrapport, utveckling samt planer.
Intervjun genomfördes av FinWire i samband med att AlzeCure Pharma slÀppte sin senaste kvartalsrapport den 5 maj 2026.
Se intervjun hÀr: https://t.co/1iMFf9ou5e
Till pressreleasen om kvartalsrapporten: https://t.co/OCJF0Yyi2k
#alzecure #neurorestore #acd856 #alzheimer #dementia #neuroscience #alzheimerfonden #nordnet #avanza #erikpenserbank #redeye #aktiespararna #swedbank #analysguiden#finwire #Alzstatin #gammasecretasmodulator #trkanam #acd440
#LifeScienceClusterFlemingsberg #flemingbergsscience #flemingbergscience #kvartalsrapport #abgsundalcollier
AlzeCure Pharma published Q1 2026 report.
Continued positive development
âDuring the first quarter of 2026, our focus was on preparing the Phase II study in Alzheimerâs patients with NeuroRestore ACD856, for which we were awarded a grant of EUR 2.5 million from the European Innovation Council (EIC). In addition, we successfully advanced the Phase Ib clinical trial with ACD856, further expanding the therapeutic dose window to increase our opportunities to address multiple indications. During the quarter, we also continued preparing for a potential registrational study for the pain project Painless ACD440. In February, ACD440 was granted orphan drug designation by the European Medicines Agency. We also remained active in business development at international conferences and published new data from our NeuroRestore project at the world-leading Alzheimerâs conference AD/PD 2026, which was held in Copenhagen in March.â â Martin Jönsson, CEO
Significant events during the period January â March 2026
In February 2026, the pain project ACD440 was granted orphan drug designation in Europe by the EMA.
AlzeCure presented new preclinical data concerning NeuroRestore ACD856 at the AD/PD Alzheimerâs conference in mid-March.
Significant events after the end of the period
In April, the company announces that the last participant has completed treatment in AlzeCure's clinical phase Ib study with NeuroRestore ACD856.
In April, the board of directors, supported by the authorization granted by the Annual General Meeting on May 14, 2025, decides to carry out a rights issue of approximately SEK 30.1 million. The issue is, free of charge, 100 percent secured.
Read the full report here: https://t.co/WBgGVfhLuG
#alzecure #interimreport #avanza #nordnet #abgsundalcollier #aktiespararna #redeye #swedbank AlzeCure Pharma Life Science Cluster Flemingsberg
New AlzeCure publication on our pain project TrkA-NAM targeting osteoarthritis
Our article on the analgesic and knee joint protective effects of TrkA-NAM ACD137 in a model of osteoarthritis is now available online. In moments like this, I miss paper reprints, so I settled for this AI-generated 'happy scientist figure' with a virtual preprint.
TrkA-NAM ACD137 is a highly potent and selective negative allosteric modulator of TrkA for the treatment of pain.
The on-line version can be found using the link below: https://t.co/rBiOvjmmQn
#TrkA #NGF #pain #ScandinavianJournalofpain #osteoarthritis #trkanam #osteoarthritis #painmanagement #neurpathicpain #nociceptivpain #AlzeCure #trkanam #osteoarthritis#painmanagement #neurpathicpain #nociceptivpain Pontus Forsell MĂ€rta Segerdahl Johan Sandin Maria Backlund Cristina Parrado Veronica Lidell Gunnar Nordvall AlzeCure Pharma Life Science Cluster Flemingsberg
Intervju om AlzeCures förestÄende företrÀdesemission under maj 2026
Intervju hos Redeye av analytikern Filip Lindkvist med AlzeCures vd Martin Jönsson om den förestÄende företrÀdesemissionen som AlzeCure kommer genomföra under maj 2026 vilken redan Àr sÀkrad till 100%, utan ersÀttning till externa parter. Bolaget planerar att ta in drygt 30,1 MSEK
Se intervjun hÀr: https://t.co/y6ZEQajjET
Till pressreleasen om emissionen: https://t.co/LpTdmvVbiZ
#alzecure #emission #abgsundalcollier #redeye #aktiespararna #avanza #nordnet #swedbank
AlzeCure Pharma carries out a fully secured rights issue of approximately SEK 30.1 million
AlzeCure today announced that the Board of Directors has resolved on a new share issue of approximately SEK 30.1 million, in a coming rights issue, which is secured to 100%, without cost for the Company.
AlzeCure is currently engaged in active and concrete discussions with several external parties regarding potential licensing and collaboration agreements for the Company's drug candidates. The Rights Issue is carried out to strengthen the cash position and provide resources for business development, pending these discussions.
The Rights Issue is fully secured to 100 percent as the Company's two major shareholders, BWG Invest SĂ rl and Sjuenda Holding AB, have undertaken, free of charge, to subscribe for all shares not subscribed for by other shareholders or subscription rights holders. Subscription undertakings from the Company's two major shareholders, Board of Directors, management and other larger shareholders amount to approximately SEK 9.3 million, corresponding to approximately 31 percent of the Rights Issue.
"We are very pleased that our major shareholders, as well as all members of the Board of Directors, support our projects by committing to subscribe for their respective pro-rata shares in the Rights Issue. The Company is now at a stage where business development is critical to realizing the value inherent in the project portfolio. The Company is engaged in active discussions with several parties regarding potential licensing and collaboration agreements, and through this share issue the cash position is strengthened to intensify out-licensing efforts and capitalize on the opportunities being discussed. The strong support from existing shareholders means that the transaction is, free of charge, 100% secured, which is very positive," says Martin Jönsson, CEO of AlzeCure Pharma AB.
The subscription price is SEK 1.31 per share.
Read the full press release here: https://t.co/qaLBtkr6fl
#alzecure #nyemission #emission #rightissue #alzheimers AlzeCure Pharma ABG Sundal CollierLife Science Cluster Flemingsberg Stiftelsen Flemingsberg Science Martin JönssonAlzheimerfonden
AlzeCure Pharma genomför en till 100 procent sÀkerstÀlld företrÀdesemission om ca 30,1 MSEK
AlzeCure meddelade idag att styrelsen har beslutat att genomföra en företrÀdesemission om cirka 30,1 MSEK vilken Àr till 100% sÀkerstÀlld till utan kostnad för bolaget, dvs ingen ersÀttning för att teckna i emissionen kommer att betalas.
AlzeCure för idag aktiva och konkreta samtal med flera externa aktörer kring möjliga licens- och samarbetsaffÀrer avseende bolagets lÀkemedelskandidater. FöretrÀdesemissionen genomförs för att stÀrka kassan och ge resurser till affÀrsutveckling, i avvaktan pÄ dessa samtal.
FöretrÀdesemissionen Àr till 100 procent sÀkerstÀlld genom att Bolagets tvÄ huvudÀgare, BWG Invest Sà rl och Sjuenda Holding AB, vederlagsfritt, förbinder sig att teckna samtliga aktier som inte tecknas av andra aktieÀgare eller teckningsberÀttigade.
Teckningsförbindelser frÄn Bolagets tvÄ huvudÀgare, styrelse, ledning och andra större aktieÀgare uppgÄr till cirka 9,3 MSEK, motsvarande cirka 31 procent av FöretrÀdesemissionen.
âDet Ă€r mycket glĂ€djande att vĂ„ra större Ă€gare, sĂ„vĂ€l som samtliga styrelsemedlemmar stödjer vĂ„ra projekt genom att förbinda sig att teckna sina respektive andelar av FöretrĂ€desemissionen. Bolaget befinner sig nu i en fas dĂ€r affĂ€rsutveckling Ă€r avgörande för att realisera det vĂ€rde som finns i projektportföljen. Bolaget för aktiva
diskussioner med flera aktörer om eventuella licens- och samarbetsaffĂ€rer och genom denna emission stĂ€rks kassan för att kunna intensifiera utlicensieringsarbetet och utnyttja de möjligheter som diskuteras. Det starka stödet av existerande Ă€gare gör att transaktionen, vederlagsfritt, Ă€r 100% sĂ€kerstĂ€lld, vilket kĂ€nns mycket positivt,â sĂ€ger Martin Jönsson, VD pĂ„ AlzeCure Pharma AB.
Teckningskursen Àr satt till 1,31 SEK.
LÀs den fullstÀndiga pressreleasen hÀr: https://t.co/LpTdmvVbiZ
#alzecure #nyemission #emission #rightissue #alzheimers AlzeCure Pharma ABG Sundal Collier Life Science Cluster Flemingsberg Stiftelsen Flemingsberg Science Martin Jönsson
Attending Nordic Health Summit Japan
- April 23-24th 2026
Happy to attend the Nordic Health Summit in Japan, Tokyo to present AlzeCure and our projects in Alzheimerâs and pain for pharmacies companies, investors and other potential partners.
This year the meeting is also having Japanâs Nobel Prize laureate in medicine from 2025, Professor Shimon Sakaguchi, attending the conference and giving a lecture, which is generating additional attention and attendees, and strengthens the ties and relationships between Japan and Sweden.
The meeting is arranged by Business Sweden together with several other Nordic organisations.
More on Professor Shimon Sakaguchi: https://t.co/mugCNXqMjT
#alzecure #businesssweden #flemingsbergsscience #nobelprize #alzheimers Martin Jönsson AlzeCure Pharma Life Science Cluster Flemingsberg Stiftelsen Flemingsberg Science Business Sweden SwedenBIO
Last patient completed in the additional 1b with NeuroRestore
AlzeCure Pharma announces an important milestone: the last patient has now completed the additional Phase Ib clinical study of ACD856, the lead candidate within the NeuroRestore platform.
The study has progressed according to plan and focuses on evaluating safety, tolerability, and pharmacokinetics at higher repeated doses. ACD856 has previously demonstrated a strong safety profile and the ability to reach the brain and activate pathways linked to cognition and depression.
This progress supports continued development toward Phase II, with potential applications not only in Alzheimerâs disease but also in other areas with significant unmet medical need, such as depression.
ACD856 is a first-in-class candidate with a unique mechanism that may strengthen neuronal communication, improve cognitive function, and offer neuroprotective and anti-inflammatory effects.
Read the full press release here: https://t.co/jnYgCzG9jo
#AlzeCure #Biotech #ClinicalTrials #DrugDevelopment #Neuroscience #Alzheimers #CNS #Pharma #Innovation #Depression #NeuroRestore Johan Sandin Martin Jönsson AlzeCure Pharma
Continuing Progress in AlzeCure
- AlzeCure Pharma Annual Report 2025.
"With strong progress and many positive events in 2025, our main priority going forward is to prepare for the Phase II clinical trial in Alzheimerâs patients with NeuroRestore ACD856, for which we have received a grant from the EIC. We continue to prepare both our pain project in knee osteoarthritis, TrkA-NAM ACD137, and Alzstatin ACD680 for Phase I clinical trials. We also remain strongly focused on business development with the aim of out-licensing one or more of our projects, including the pain project, ACD440."
Martin Jönsson
CEO of AlzeCure Pharma
Read the full report here: https://t.co/LC4xqraIvp
#AlzeCurePharma #PainResearch #Alzheimers #ClinicalDevelopment#Innovation Martin Jönsson
AlzeCure presenterar pĂ„ Redeye Alzheimerâs Event
- 9 april
AlzeCure kommer att medverka pĂ„ Redeye Alzheimerâs Theme Event den 9 april dĂ€r VD Martin Jönsson och CSO Johan Sandin kommer att presentera bolaget och dess projektportfölj inom Alzheimers.
Presentationen följs av en frÄgestund ledd av Redeyes analytiker Filip Lindkvist.
Deltagandet livesÀnds och kan följas pÄ:
https://t.co/0YKGioLgGf
AlzeCure kommer presentera kl. 11:15 den 9 april 2026
Plats: Redeye, MĂ€ster Samuelsgatan 42, Stockholm; https://t.co/0YKGioLgGf
#alzecure #redeye #alzheimer Stiftelsen Flemingsberg Science Life Science Cluster Flemingsberg Martin Jönsson Johan Sandin
Presentation om AlzeCure Pharma hos Aktiespararna av CEO Martin Jönsson
Presentation om AlzeCure Pharma av CEO Martin Jönsson om bolaget och dess projekt inom Alzheimer och smÀrta, samt om den senaste utvecklingen och bolagets planer.
Presentationen hölls hos Aktiespararna pÄ Stora Aktiedagarna i Stockholm den 11 mars 2026.
Till presentationen: https://t.co/miKY1z4NTE
#aktiespararna #analysguiden #alzecure
Great Bio Europe in Lisbon
- Now it's over, and time for follow-ups
Very happy with this yearâs Bio Europe Spring in Lisbon, meeting pharma companies, partners and investors, presenting and giving an update on AlzeCureâs projects and plans for our projects in Alzheimerâs and pain.
Now itâs time to go home and do all the follow-up based on fruitful meeting.
Happy to have been joined by my friends at Sprint Bioscience, Anne-Marie Wenthzel-Buckhöj and Martin Andersson
Read more on Alzecure and our projects at https://t.co/JorDOcorMT
#newtherapies
#drugdevelopment
#BIOEuropeSpring AlzeCure Pharma Martin Jönsson
#sprintbioscience Anne-Marie Wenthzel-Buckhöj Martin Andersson AlzeCure PharmaLife Science Cluster Flemingsberg SwedenBIO Business Sweden Martin Jönsson